SCHEDULE: ADAR1 Capital Discloses 9.9% Stake in Inhibikase

ADAR1 Capital Management and Daniel Schneeberger have reported a 9.9% beneficial ownership stake in Inhibikase Therapeutics, Inc.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger filed a Schedule 13G reporting collective beneficial ownership of 13,860,028 shares of Inhibikase Therapeutics, Inc.
• The reported stake represents 9.9% of the company's outstanding common stock, based on 132,032,636 shares outstanding as of March 31, 2026.
• The holdings include 4,786,694 shares held by ADAR1 Partners, LP, 694,329 shares held by Spearhead Insurance Solutions IDF, LLC, 510,949 shares held by ADAR1 SPV I, LP, 614,600 shares in managed accounts, and 7,253,456 shares underlying milestone warrants.
• The filing confirms the acquisition was made in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects institutional confidence in the company's underlying assets without the volatility associated with activist campaigns.

Positives

• Significant institutional interest from ADAR1 Capital Management, signaling confidence in the company's long-term prospects.
• The reporting persons have explicitly stated the investment is passive, reducing immediate concerns regarding hostile takeover or activist intervention.

Negatives

• The stake includes a substantial portion (7,253,456 shares) of milestone warrants, which could lead to future dilution if exercised.

Risks

• Potential for future share dilution upon the exercise of the 7,253,456 milestone warrants held by the reporting entities.
• Market volatility associated with significant institutional ownership shifts.

Future Outlook

The reporting persons maintain a passive investment stance, indicating no current plans to influence corporate strategy or control.

Industry Context

StockSavvy.ai notes that institutional filings of this nature are common in the biotechnology sector, where specialized investment firms often take significant positions in companies with upcoming clinical milestones or regulatory catalysts.

Comparison to Industry Standards

• The 9.9% ownership threshold is a standard reporting level for institutional investors seeking to maintain a significant but passive position just below the 10% reporting trigger for certain regulatory requirements.

Stakeholder Impact

• Shareholders may view the entry of a significant institutional investor as a validation of the company's clinical or business strategy.

Next Steps

• Continued monitoring of ADAR1 Capital Management's holdings for any future changes in investment intent or stake size.

Key Dates

Keywords

Inhibikase Therapeutics, IKT, Schedule 13G, ADAR1 Capital Management, Institutional Ownership, Biotech Investment, Milestone Warrants